Background: Breast cancer is the most common cancer and the leading cause of cancer-related deaths among women worldwide. The annual global incidence of breast cancer is estimated to be >1.3 million cases and approximately 465,000 women die of this disease every year. Osteoporosis is a common chronic problem in postmenopausal women that increases the risk for spinal compression fractures and fractures of the femoral neck, causing life-threatening complications. Cancer-induced osteoporosis is a long-term complication associated with cancer therapy that can directly or indirectly affect bone metabolism. The change in rate of bone metabolism is reflected much earlier in biochemical markers than by bone mineral densitometry. Objective: To analyze the change in serum bone resorption marker, CTelopeptide (CTX) before and after the treatment in patients of carcinoma breast. Method: This prospective clinical study involves 27 histopathologically proven cases of carcinoma breast patients which was conducted during October 2017 to August 2018 to analyze the change in serum bone resorption marker, CTelopeptide (CTX) before and after the treatment in patients of carcinoma breast. In this study, frequency tables with counts and percentages are used to describe pre-treatment and treatment characteristics for each group .The categorical clinical characteristics between the two treatments are compared using chi-square test. Result: in this study the Majority of the patients had stage IIIB and IIB disease 12 out of 27(44.4%) patients presented with IIIB disease, 9 out of 27(33.3%) belongs to stage IIB, 4 out of 27 (14.8) were in IIIA, 3 patients out of 27(11.1%) had IIIC disease. The mean pre-treatment serum CTX level was 19.52±3.3 µg/ml and mean post-treatment serum CTX was 75.79±18.19 µg/ml ,highly significant difference was found between the mean pre and post-treatment serum CTX level in postmenopausal group (p=0.0001), it is statistically insignificant in pre-menopausal patients (p=0.460).Conclusion: Osteoporosis is a common chronic problem in postmenopausal women that increases the risk for spinal compression fractures and fractures of the femoral neck, causing life-threatening complications in older women. Women treated for cancer may be at risk for osteoporosis and fracture. Cancer-induced osteoporosis is a long-term complication associated with cancer therapy that can directly or indirectly affect bone metabolism. Serum biochemical bone turnover markers (BTM) are used in the management of bone diseases including postmenopausal osteoporosis (PMO). Among bone resorption markers, serum C-Telopeptide cross-link of type 1 collagen (CTX) is a highly sensitive indicator of bone resorption. By analysing the CTX before and after treatment can help cancer patients to know the grade of osteoporosis hence the appropriate treatment modality.
